Procaine amide hydrochloride was first introduced clinically by Mark et al. (1950) . They drew attention to its effectiveness in the control of ventricular arrhythmias, especially paroxysmal ventricular tachycardia. This has since been amply confirmed. It is the drug of choice in the treatment of paroxysmal ventricular tachycardia, taking precedence over the more toxic and unpredictable quinidine. By contrast, reliance on procaine amide for the control of the supraventricular tachycardias is unwise, although it is frequently effective in the paroxysmal auricular and nodal tachycardias (Miller et al., 1951; Berry et al., 1951) .
has shown, in the experimental animal, by means of high-speed cinematography and direct lead electrocardiography, the unitary nature of auricular tachycardia and auricular flutter, we have preferred to label the present arrhythmia as auricular flutter with 1: 1 A-V conduction.
The dramatic response, probably life-saving, we witnessed in the present case is worthy of further comment. East and Bain (1948) state " the human ventricle is not capable of maintaining rates of over 300, and speeds of over 200 are not well tolerated," while Gold (1950) states " a rate (ventricular) of 230 a minute fatigues and damages the circulation." In the present case with a ventricular rate of 260 a minute, maintained for three hours, and with absent peripheral pulses, the prognosis could rightly be regarded as grave. The abrupt response occurring during intravenous procaine amide therapy could scarcely have been fortuitous, or indeed the result of previous morphine administration, although the latter may at times control cardiac arrhythmias (Sabathie, 1947) . Of additional interest was the relief of pain, following the procaine amide injection. This information has been volunteered by other patients treated with intravenous procaine amide and would be predicted from the known local anasthetic properties of procaine derivatives.
Finally, it must be recognized that procaine amide is a potent drug, and its slow intravenous administration must be accompanied by electrocardiographic control, with immediate availability of appropriate antidotes to cover side-effects.
SUMMARY
A case of coronary thrombosis complicated by auricular flutter with I: 1 A-V conduction is described. The patient was in extremis at the time of starting intravenous procaine amide therapy. He regained sinus rhythm after 6 ml. (0-6 g.) had been injected over three minutes, and his further recovery was uneventful.
